Merrimack Pharma Cutting Jobs Again After Shelving Third Cancer Drug In Year
Merrimack Pharmaceuticals is ending development of its lead drug MM-310 because of safety concerns, triggering a fresh round of job cuts at the troubled Cambridge, Massachusetts-based biotech.
You may also be interested in...
Merrimack's wind-down continues with an activist challenge, but investors approved the Vical/Brickell Biotech reverse merger. Also, the past month's IPO slump may reverse course and HiFiBiO's $67m Series C leads recent financings.
The VC firm known for its new company formation efforts will launch 10-12 biopharma, device and diagnostic ventures with its fifth fund. Also, EpimAb raises a $74m series B round, three more drug developers join the IPO queue and Amicus leads recent follow-on offerings.
The Global AMR R&D Hub’s newly launched Dynamic Dashboard aims to be “a comprehensive knowledge center for AMR R&D and market reforms,” its head tells Scrip.